Literature DB >> 11224422

Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors.

J. Romero1, E. García-Palomero, J.J. Fernández-Ruiz, J.A. Ramos.   

Abstract

The present study was designed to investigate the possibility of activation of GABA(B) receptors during the motor inhibition caused by cannabimimetics. Adult male rats were injected with an acute dose of arachidonylethanolamide (AEA), Delta(9)- tetrahydrocannabinol (THC), beclofen or vehicle, after pretreatment with CGP 35348, a specific antagonist for GABA(B) receptors, or vehicle, and the behavioral response produced by these compounds tested in an open field. As expected, the administration of either AEA or THC produced a very pronounced motor inhibition, reflected by decreased ambulation and increased time spent in inactivity. The administration of baclofen also produced a marked motor deficit, with similar changes to those observed with both cannabimimetics. Pretreatment with the GABA(B) antagonist, CGP 35348, prevented the motor inhibition induced by baclofen and also attenuated the motor deficit caused by both cannabimimetics, suggesting a role for this receptor. In summary, a GABAergic influence, acting through GABA(B) receptors, seems to be involved in mediating motor effects of cannabimimetics, since the blockade of these receptors attenuates cannabimimetic-induced signs of motor inhibition.

Entities:  

Year:  1996        PMID: 11224422     DOI: 10.1097/00008877-199605000-00011

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  9 in total

1.  Pretreatment with Δ9-tetrahydrocannabinol (THC) increases cocaine-stimulated activity in adolescent but not adult male rats.

Authors:  Diana Dow-Edwards; Sari Izenwasser
Journal:  Pharmacol Biochem Behav       Date:  2011-09-17       Impact factor: 3.533

Review 2.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

3.  Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.

Authors:  J Romero; F Berrendero; L García-Gil; J A Ramos; J J Fernández-Ruiz
Journal:  J Mol Neurosci       Date:  1998-10       Impact factor: 3.444

4.  Separate and combined effects of the GABA(B) agonist baclofen and Δ9-THC in humans discriminating Δ9-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2012-06-13       Impact factor: 4.492

5.  Olfactory Hallucinations without Clinical Motor Activity: A Comparison of Unirhinal with Birhinal Phantosmia.

Authors:  Robert I Henkin; Samuel J Potolicchio; Lucien M Levy
Journal:  Brain Sci       Date:  2013-11-15

6.  Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia.

Authors:  F Rodríguez De Fonseca; M A Gorriti; A Bilbao; L Escuredo; L M García-Segura; D Piomelli; M Navarro
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 7.  The endocannabinoid system as a target for the treatment of motor dysfunction.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

8.  Exposure to cannabinoids in the development of endogenous cannabinoid system.

Authors:  José A Ramos; Rosario De Miguel; Maribel Cebeira; Mariluz Hernandez; Javier Fernández-Ruiz
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

9.  Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Thomas H Kelly; David J Pinsky; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2008-11-19       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.